Donald L. Weaver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Donald L. Weaver has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Allison Hall
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
21 shared publications - Carlo C. Maley
Arizona Cancer Evolution Center, The Biodesign Institute, Arizona State University
21 shared publications - Daniel Monyak
Trinity College of Arts and Sciences, Duke University; Durham, NC, USA
21 shared publications - Darryl Shibata
Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
21 shared publications - Diego Mallo
Arizona Cancer Evolution Center, The Biodesign Institute, Arizona State University, Tempe, Arizona
21 shared publications - E. Shelley Hwang
Department of Surgery, Duke University Medical Center, Durham, NC
21 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 1. Frequencies of the most common combinations of benign breast disease diagnoses occurring within the same biopsy episode among women with multiple diagnoses.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 1. Frequencies of the most common combinations of benign breast disease diagnoses occurring within the same biopsy episode among women with multiple diagnoses.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 12 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 12. Hazard ratios and 95% confidence intervals for associations between individual benign breast disease diagnoses and subsequent ductal carcinoma in situ according to menopausal status.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 12 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 12. Hazard ratios and 95% confidence intervals for associations between individual benign breast disease diagnoses and subsequent ductal carcinoma in situ according to menopausal status.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Background:Benign breast disease (BBD) increases breast cancer risk; however, associations between specific BBD diagnoses and breast cancer risk are insufficiently studied. Methods:We analyzed 131,075 benign breast biopsy episodes from 1994 to 2022 identified from eight Breast Cancer Surveillance Consortium registries. Pathologic diagnoses were classified into 38 BBDs within 4 categories. For comparison, women with no prior breast biopsy and a negative screening mammogram (N = 1,599,694) were identified. Associations of BBDs with invasive breast carcinoma and ductal carcinoma in situ (DCIS) were estimated using Fine–Gray competing risk models. Results:Over a median follow-up of 7.5 years, 35,251 invasive breast cancers and 9,743 DCIS cases occurred. Lobular carcinoma in situ was associated with a 5.61-fold [95% confidence interval (CI), 4.10–7.68] increased risk of invasive carcinoma and an 8.82-fold (95% CI, 5.39–14.4) increased risk of DCIS. Among proliferative changes with atypia BBDs, invasive cancer hazard ratios (HR) ranged from 2.76 to 4.85; DCIS HRs ranged from 5.07 to 8.51. Among proliferative changes without atypia BBDs, invasive HRs ranged from near-null (papillomatosis) to moderate and strong associations (e.g., HR, 1.55 for usual ductal hyperplasia and 2.84 for multiple papillomas); DCIS HRs ranged from 1.37 to 5.04. Nonproliferative BBDs were associated with low-to-moderate risk (invasive HRs, 0.63 for atrophy to 2.16 for benign breast parenchyma; DCIS HRs, 0.66–4.29). Most associations declined with increasing time since biopsy. Conclusions:Associations between BBDs and breast cancer varied widely within commonly used histologic categories. Impact:Advancing knowledge of specific BBD diagnoses may improve breast cancer risk prediction and support targeted screening and prevention strategies.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Background:Benign breast disease (BBD) increases breast cancer risk; however, associations between specific BBD diagnoses and breast cancer risk are insufficiently studied. Methods:We analyzed 131,075 benign breast biopsy episodes from 1994 to 2022 identified from eight Breast Cancer Surveillance Consortium registries. Pathologic diagnoses were classified into 38 BBDs within 4 categories. For comparison, women with no prior breast biopsy and a negative screening mammogram (N = 1,599,694) were identified. Associations of BBDs with invasive breast carcinoma and ductal carcinoma in situ (DCIS) were estimated using Fine–Gray competing risk models. Results:Over a median follow-up of 7.5 years, 35,251 invasive breast cancers and 9,743 DCIS cases occurred. Lobular carcinoma in situ was associated with a 5.61-fold [95% confidence interval (CI), 4.10–7.68] increased risk of invasive carcinoma and an 8.82-fold (95% CI, 5.39–14.4) increased risk of DCIS. Among proliferative changes with atypia BBDs, invasive cancer hazard ratios (HR) ranged from 2.76 to 4.85; DCIS HRs ranged from 5.07 to 8.51. Among proliferative changes without atypia BBDs, invasive HRs ranged from near-null (papillomatosis) to moderate and strong associations (e.g., HR, 1.55 for usual ductal hyperplasia and 2.84 for multiple papillomas); DCIS HRs ranged from 1.37 to 5.04. Nonproliferative BBDs were associated with low-to-moderate risk (invasive HRs, 0.63 for atrophy to 2.16 for benign breast parenchyma; DCIS HRs, 0.66–4.29). Most associations declined with increasing time since biopsy. Conclusions:Associations between BBDs and breast cancer varied widely within commonly used histologic categories. Impact:Advancing knowledge of specific BBD diagnoses may improve breast cancer risk prediction and support targeted screening and prevention strategies.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 10 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 10. Hazard ratios and 95% confidence intervals for associations between individual benign breast disease diagnoses and subsequent ductal carcinoma in situ.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 10 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 10. Hazard ratios and 95% confidence intervals for associations between individual benign breast disease diagnoses and subsequent ductal carcinoma in situ.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 11 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 11. Hazard ratios and 95% confidence intervals for associations between individual benign breast disease diagnoses and subsequent invasive breast cancer according to menopausal status.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 11 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 11. Hazard ratios and 95% confidence intervals for associations between individual benign breast disease diagnoses and subsequent invasive breast cancer according to menopausal status.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 13 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 13. Hazard ratios and 95% confidence intervals for associations between broad benign breast disease histologic categories and invasive breast cancer according to time since biopsy or mammogram and menopausal status.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 13 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 13. Hazard ratios and 95% confidence intervals for associations between broad benign breast disease histologic categories and invasive breast cancer according to time since biopsy or mammogram and menopausal status.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 14 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 14. Hazard ratios and 95% confidence intervals for associations between broad benign breast disease histologic categories and ductal carcinoma in situ according to time since biopsy or mammogram and menopausal status.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 14 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 14. Hazard ratios and 95% confidence intervals for associations between broad benign breast disease histologic categories and ductal carcinoma in situ according to time since biopsy or mammogram and menopausal status.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 2. Frequencies of the most common diagnosis combinations that include columnar cell lesions within the same biopsy episode.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 2. Frequencies of the most common diagnosis combinations that include columnar cell lesions within the same biopsy episode.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 3. Frequencies of the most common diagnosis combinations that include papillomatosis within the same biopsy episode.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 3. Frequencies of the most common diagnosis combinations that include papillomatosis within the same biopsy episode.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 4. Frequencies of the most common diagnosis combinations that include atrophy within the same biopsy episode.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Advancing Evidence of the Associations between Specific Benign Breast Disease Diagnoses and Future Breast Cancer Risk
Supplemental Table 4. Frequencies of the most common diagnosis combinations that include atrophy within the same biopsy episode.